Andere Sprachen Larimar Therapeutics, Inc.

Aktien

A2P5PP

US5171251003

LRMR

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:36:19 09.05.2024			% 5 Tage	% 1. Jan.
7,8 ^USD	-1,52 %		+2,43 %	+71,32 %

13:02	Larimar Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
13:00	Zafgen, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Larimar: Q1 Earnings Snapshot	13:26
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results	13:02
Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13:02
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13:00
North American Morning Briefing : Stock Futures -2-	19.03.
Larimar: Q4 Earnings Snapshot	14.03.
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development	14.03.
Sector Update: Health Care Stocks Gain Premarket Tuesday	12.03.
North American Morning Briefing : Inflation Data -2-	12.03.
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment	11.03.
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia	11.03.
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	11.03.
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference	06.03.
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	16.02.
Top Midday Gainers	14.02.
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock	14.02.
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants	14.02.
Larimar Therapeutics Announces Proposed Underwritten Public Offering	13.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Larimar Therapeutics, Inc.

Aktien

A2P5PP

US5171251003

LRMR

Andere Sprachen

Filter